Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (4201)	5/4/1998 7:33:00 PM
From: John F Beule	Respond to of 6136

Thanks! Boy this is exciting stuff!

To: margie who wrote (4201)	5/5/1998 12:11:00 AM
From: billkirn	Read Replies (1) \| Respond to of 6136

Margie: After talking with IR, my understanding that Agouron in close cooperation with the FDA decided to go directly to phaseIII trials. The results must be quite good to proceed directly to phase III. No public notification has been made yet as the test sites have not been selected. If all goes well, NDA in 2000. I am not sure how to compare AG3340's effectiveness against Entremed's candidate, but our baby seems to be far ahead of the competition. Let us hope AG3340 is at least in the ball park of the expected Entremed's effectiveness. Since there has been no reported of exceptional effectiveness for AG3340, I don't expect miracles but a solid performer. Bill